The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
In its second year, the Society of Hematologic Oncology (SOHO) will host its virtual SOHO Breakthroughs in Blood Cancers (SBBC) meeting, chaired by Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center. This global event will be held from 8:00 am to 4:40 pm CDT on Thursday, November 12, 2026.
The National Medical Products Administration (NMPA) of China accepted the investigational New Drug application for the immunotherapy 6MW5311, a LILRB4/CD3 T-cell engager bispecific antibody, to treat patients with acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma.
In this SOHO Insider interview from the 2026 AACR Annual Meeting, Roy Jensen, MD, vice chancellor and director of the University of Kansas Cancer Center (KU Cancer Center), discusses point-of-care CAR-T manufacturing and the regulatory challenges associated with the process.
In vivo CAR-T therapy, which eliminates the complex manufacturing required for current ex vivo approaches, could represent the next generation of treatment, but early data raise safety concerns, including inflammatory toxicity, according to a presentation by Saar Gill, MD, PhD, an associate professor of medicine, at the University of Pennsylvania.
In this SOHO Insider podcast, host Megan Melody, MD, from Tampa General Hospital, spoke with Nirav Shah, MD, professor at the Medical College of Wisconsin,
To access the SOHO Career Center click the following link.
